Skip to main content

Table 4 Associations of confirmed SARS-CoV-2 infection. Bivariable analysis

From: Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

  OR 95% CI p AUC
Hypertension
 Hypertension 1.73 1.14 to 2.64 0.01 0.66
 PDN 3.04 2.09 to 4.43 < 0.001  
 Hypertension 2.04 1.18 to 3.53 0.01 0.61
 csDMARDs 1.74 0.53 to 5.72 0.37  
 Hypertension 1.81 1.47 to 2.24 < 0.001 0.64
 b/tsDMARDs 0.46 0.18 to 1.21 0.12  
Home lockdown
 Home lockdown 0.55 0.35 to 0.85 0.008 0.67
 PDN 3.20 1.97 to 5.18 < 0.001  
 Home lockdown 0.62 0.40 to 0.95 0.03 0.59
 csDMARDs 1.58 0.66 to 3.77 0.31  
 Home lockdown 0.63 0.46 to 0.85 0.002 0.63
 b/tsDMARDs 0.51 0.11 to 2.29 0.38  
Contacts with COVID-19
 Contacts with COVID-19 12.74 2.38 to 68.30 0.003 0.74
 PDN 3.14 1.72 to 5.73 < 0.001  
 Contacts with COVID-19 13.33 2.08 to 85.40 0.006 0.68
 csDMARDs 1.77 0.60 to 5.21 0.30  
 Contacts with COVID-19 11.76 1.74 to 79.51 0.01 0.68
 b/tsDMARDs 0.48 0.12 to 1.92 0.30  
Treatment
 PDN 2.70 1.34 to 5.46 0.006 0.65
 csDMARDs 1.56 0.45 to 5.35 0.48  
 PDN 2.67 1.84 to 3.86 < 0.001 0.67
 b/tsDMARDs 0.51 0.18 to 1.44 0.21  
 csDMARDs 1.72 0.51 to 5.84 0.38 0.62
 b/tsDMARDs 0.47 0.15 to 1.53 0.21  
  1. PDN prednisone, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, b/ts DMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs